Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Oral Metadon i Hjertekirurgi (OMICS)

27. oktober 2026 oppdatert av: Krishnan Ramanujan, Mayo Clinic

The purpose of this study is to compare the effects of administration of oral methadone preoperatively and intravenous methadone upon induction of general anesthesia on postoperative pain for patients undergoing elective cardiac surgery.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

100

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic in Rochester

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

• Undergoing elective cardiac surgery

Exclusion Criteria:

  • Chronic pain requiring opioid medications as an outpatient
  • Opioid use disorder on medication assistance treatment
  • Prolonged QTc >500ms
  • Chronic kidney disease with eGFR < 30mL/min
  • Documented cirrhosis
  • Intolerance to methadone
  • Admitted inpatient in an intensive care unit (ICU) immediately prior to surgery
  • Pregnancy at the time of surgery
  • Subsequent surgeries after index surgery

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Intravenous methadone intraoperatively

Subjects in the IV methadone arm will receive methadone intravenously during cardiac surgery

Patients will receive 0.3mg/kg methadone intravenously after induction of general anesthesia

Eksperimentell: Oral methadone, immediately prior to transport

Subjects in the oral methadone arm will receive methadone orally prior to cardiac surgery

Patients will receive 0.4mg/kg PO methadone immediately prior to transport to the operating room

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Amount of opioid medication used 72 hours post-extubation
Tidsramme: From hospital admission for surgery to 72 hours after the patient is extubated postoperatively

Opioid medication used at 72 hours post-extubation will be reported in morphine milligram equivalents

From hospital admission for surgery to 72 hours after the patient is extubated postoperatively

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Amount of opioid medication used 24 hours post-extubation
Tidsramme: From hospital admission for surgery to 24 hours after the patient is extubated postoperatively

Opioid medication used at 24 hours post-extubation will be reported in morphine milligram equivalents

From hospital admission for surgery to 24 hours after the patient is extubated postoperatively
Amount of opioid medication used 48 hours post-extubation
Tidsramme: From hospital admission for surgery to 48 hours after the patient is extubated postoperatively

Opioid medication used at 48 hours post-extubation will be reported in morphine milligram equivalents

From hospital admission for surgery to 48 hours after the patient is extubated postoperatively
Amount of opioid medication required throughout hospitalization
Tidsramme: From the time the patient is extubated until the time the patient leaves the hospital, approximately 10 days. Safety to leave the hospital is determined by the cardiac surgery team and can be several days after surgery or longer.

Opioid medication required from extubation until hospital discharge will be reported in morphine milligram equivalents

From the time the patient is extubated until the time the patient leaves the hospital, approximately 10 days. Safety to leave the hospital is determined by the cardiac surgery team and can be several days after surgery or longer.
Amount of opioid medication required prior to extubation
Tidsramme: From arrival in the ICU until extubation, approximately 6 hours. Safety of extubation is determined by the intensive care unit team and usually occurs within several hours of ICU arrival, although this can be variable.

Opioid medication required between the end of surgery and extubation will be documented in morphine milligram equivalents.

From arrival in the ICU until extubation, approximately 6 hours. Safety of extubation is determined by the intensive care unit team and usually occurs within several hours of ICU arrival, although this can be variable.
Pain scores after extubation
Tidsramme: 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after extubation

Pain will be assessed by nursing staff using a numerical rating scale from 0-10, with 0 being no pain and 10 being the worst pain imaginable.

6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after extubation
Time to extubation
Tidsramme: From the time the patient arrives in the ICU intubated until the time they are successfully extubated, approximately 12 hours. Safety of extubation is determined by the ICU team and usually occurs within several hours, although this can be variable.

This outcome will monitor the time in minutes from when a patient arrives in the ICU to the time the breathing tube is removed (extubation).

From the time the patient arrives in the ICU intubated until the time they are successfully extubated, approximately 12 hours. Safety of extubation is determined by the ICU team and usually occurs within several hours, although this can be variable.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Krishnan Ramanujan, M.D., Mayo Clinic

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. januar 2026

Primær fullføring (Faktiske)

22. august 2026

Studiet fullført (Faktiske)

25. oktober 2026

Datoer for studieregistrering

Først innsendt

25. oktober 2025

Først innsendt som oppfylte QC-kriteriene

25. oktober 2025

Først lagt ut (Faktiske)

28. oktober 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere